The global cardiovascular drugs market was valued at approximately
US$ 80.0 Bn in 2016 is projected to register cumulative annual growth
rate (CAGR) of over 1.0% from 2017 to 2025, according to a new report
published by Transparency Market Research (TMR) titled
“Cardiovascular Drugs Market – Global Industry Analysis, Size,
Share, Growth, Trends, and Forecast, 2017–2025”. The report
suggests that surge in incidences of hypertension and hyperlipidemia
is likely to spur the demand of cardiovascular drugs in the coming
years (2017 to 2025). As key players introduce their new
cardiovascular drugs in developed markets such a North America and
Western Europe, these regions are likely to account for dominating
share of the global cardiovascular drugs market. Changing dietary
habits and sedentary lifestyle trends in emerging markets such as
China and India is likely to boost growth of Asia Pacific
cardiovascular drugs market at a CAGR of around 2.0% from 2017 to
2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33281
Cardiovascular diseases (CVD’s) are the leading cause of deaths
across the globe. According to World Health Organization’s report,
more than 17.7 million individuals died of CVDs in 2015, and CVDs
accounted for 31% of total deaths in 2013. Cardiovascular diseases
are one of the leading cause for healthcare burden in developed as
well as developing countries. Sedentary lifestyle, lack of exercise
and changing dietary habits in developed and emerging markets is
leading to cardiovascular diseases such as hypertension and
hyperlipidemia which in turn is likely to fuel uptake of
cardiovascular drugs. Many of the block buster cardiovascular drugs
have lost their patent exclusivity in recent years and many are about
to go off patent in near future. This factor has attracted many small
and mid-size industry players to offer their generic drugs, which in
turn has attributed for devaluation of the market, there by
restraining growth of global cardiovascular drugs market.
The report offers detailed segmentation of global cardiovascular
drugs market based on drug class, indication and distribution
channel. Among the drug class studied, anti-clotting agents segment
is poised to account for leading share of the global market during
the forecast period from 2017 to 2025. Anti-clotting agents segment
which comprises anticoagulants and platelet aggregation inhibitors is
likely to get boost from increasing incidences of heart failures,
stroke, etc. According to Center for Disease Control and Prevention
of the U.S., around 795,000 people in the U.S. suffer from a stroke
each year of which 610,000 are found to be first or new cases of
stroke. The renin-angiotensin system blockers segment is anticipated
to lose its market share during the forecast period, and is expected
to hold a share of ~16.0% by 2025 from ~18.0% in 2016. Availability
of generics and adverse effects associated with ACE inhibitors and
ARB’s are factors likely to hamper this segment.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=33281
Among indications, hypertension segment is projected to hold dominant
share of global cardiovascular drugs market during the forecast
period and is likely to expand at CAGR of around 1.5% from 2017 to
2025. Center for Disease Control and Prevention of the U.S. states
that ~32% of adult population in the U.S. had high blood pressure in
2012. Surge in preference for hypertension specific drugs such as
Tracleer, Letairis, etc. over conventional beta blockers, diuretics
and calcium channel blockers is projected to fuel this expansion.
Arrhythmia segment, which accounted for a meager share of global
cardiovascular drugs market is anticipated to have substantial growth
and account for approximately 4.0% of market share by 2025.
Advancements in implantable cardiovascular devices such as leadless
pacemakers, development of battery free pacemakers to treat
arrhythmia is likely to hamper arrhythmia drugs market. Retail
pharmacies are projected to be leading segment of distribution
channel over the forecast period while online pharmacies are likely
to register growth at CAGR of over 2.0% from 2017 to 2025. Adoption
of e-commerce, convenience & discounts offered by mail pharmacies
are major factors triggering this growth.
In terms of value, North America was leading contributor in global
cardiovascular drugs market in 2016. High prevalence of
hyperlipidemia and hypertension in the U.S. is one of the
contributing factor for major share of the North America market.
However, increasing foray of generic drugs in the U.S. is implying
pricing constraints on existing players which is likely to hamper
this market. According to the Association for Accessible Medicines of
the U.S., approximately 89% of the total prescriptions dispensed in
2016 in the U.S. were contributed by generic drugs. Healthcare
spending in emerging markets such as China and India are rising,
which is fueling the expansion of Asia Pacific cardiovascular drugs
market. Regaining economic growth in Latin American markets such as
Brazil is augmenting healthcare expenditure through rise in private
health insurance, entry of international drug manufacturers and
health care providers in this region. This factor is likely to propel
Latin America cardiovascular drugs market at CAGR of 1.9% from 2017
to 2025.
The report also provide profiles of leading players operating in
global cardiovascular drugs market include AstraZeneca plc., Pfizer
Inc., Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb
Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La
Roche Ltd, Abbott Laboratories, Gilead Sciences, Inc., Johnson &
Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka
Holdings Co., Ltd. and Takeda Pharmaceutical Company Limited.
Expansion of cardiovascular drugs portfolio through improving
existing drugs and developing new drug molecules is one of the key
strategy adopted by many key players, recent developments and launch
of biological drugs such as PCSK9 for treating hyperlipidemia by
Sanofi, Pfizer Inc. and other key players reflect these strategies.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment